Aileron Therapeutics Inc (ALRN)


Stock Price

About the Company

Aileron Therapeutics Inc. is a clinical-stage biopharmaceutical company that is focused on enabling patients to fight cancer without the fear or burden of chemotherapy-induced side effects. The company believes selective chemoprotection has the potential to fundamentally transform chemotherapy like anesthesia transformed surgery.





Total Revenue




Market Capitalization


Price/Earning ratio

Company News

Aileron Therapeutics Inc. (NASDAQ:ALRN) 0.0% Above Its 52-Week Low, How Long Will It Keep Rising?

3h ago, source: marketingsentinel

In last trading session, Aileron Therapeutics Inc. (NASDAQ:ALRN) saw 1.06 million shares changing hands with its beta ...

Here’s Our Rant About Aileron Therapeutics Inc. (ALRN)

1d ago, source: newsheater

Aileron Therapeutics Inc. (NASDAQ:ALRN) went down by -24.78% from its latest closing price compared to the recent 1-year high of $1.34. The company’s stock price has collected 2.82% of gains in the ...

What You Didn’t Know About Aileron Therapeutics Inc. (NASDAQ: ALRN) This Week

1d ago, source: stocksregister

Aileron Therapeutics Inc. (NASDAQ:ALRN) traded at $0.31 at last check on Wednesday, June 29, made a downward move of -24.51% on its previous day’s price. Looking at the stock we see that its previous ...

Aileron Therapeutics (NASDAQ:ALRN) Downgraded to “Market Perform” at William Blair

1d ago, source: Defense World

William Blair cut shares of Aileron Therapeutics (NASDAQ:ALRN – Get Rating) from an outperform rating to a market perform ...

Aileron Therapeutics Shares Down After Lung Cancer Data

1d ago, source: MarketWatch

Aileron Therapeutics Inc. shares were down 23% to 31.6 cents in Wednesday trading after the company said it was stopping enrollment in a lung cancer trial. The oncology company issued interim data ...

Aileron Therapeutics Inc

14d ago, source: Reuters

Aileron Therapeutics, Inc. is a clinical-stage chemoprotection oncology company. The Company is focused on developing medicines to make chemotherapy safer. ALRN-6924, is its MDM2/MDMX dual ...

Aileron Therapeutics Inc - Stock Quote ALRN

7d ago, source: Morningstar%2c Inc.

There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible ...

Aileron drug fails to beat placebo in reducing chemo toxicities in lung cancer patients in trial

2d ago, source: Seeking Alpha

Aileron Therapeutics (ALRN) said it plans to stop further enrollment in a phase 1b study of ALRN-6924 after the drug did not ...

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 39.6% in May

18d ago, source: ETF Daily News

Aileron Therapeutics, Inc. (NASDAQ:ALRN – Get Rating) was the target of a significant decline in short interest in May. As of May 31st, there was short interest totalling 197,300 shares ...

Aileron Therapeutics, Inc. (ALRN)

7d ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Aileron Therapeutics Inc (ALRN) NPV

7d ago, source: Hargreaves Lansdown

The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of ...

ALRN Aileron Therapeutics, Inc.

7d ago, source: Seeking Alpha

The chart has 1 X axis displaying Time. Data ranges from 2021-06-22 20:00:00 to 2022-06-24 17:05:37. The chart has 1 Y axis displaying values. Data ranges from -74.27 to 13.89.

My Portfolio